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CHAPTER I
INTRODUCTION
Studies utilizing a rat renal cortical slice system (1) or the
isolated, perfused rat kidney (2), suggest that peripheral dopamine
directly stimulates renin release through a beta-adrenergic receptor
mechanism similar to that postulated for norepinephrine by several investigators (3-8).

Recent studies in this laboratory (9-10) utilizing

the dopamine-beta-hydroxylase inhibitor FLA-63 which effectively prevents the conversion of dopamine to norepinephrine in in vitro tissue
(11-12), have provided added support for this view as well as for the
possibility that cyclic AMP may mediate the stimulatory effect of dopamine on renin release via this beta-receptor pathway.

However, the re-

sults obtained in these studies have left unanswered the question as to
whether or not dopamine may also influence renin secretion through an
interaction with a specific dopamine receptor located in the membranes
of the juxtaglomerular cells.
In order to effectively evaluate specific factors that may directly control renin release, various humoral and hemodynamic influences
that also affect renin secretion in vivo must first be eliminated.
Therefore, an in vitro rat kidney cortical slice preparation devoid
of these influences was utilized in this study to further examine the
type of mechanism involved in mediating a direct effect of dopamine on
renin release.

In addition, a number of in vivo and in vitro studies
1

2

have shown that the sensitivity of the renin-secreting cells to catecholamine stimulation is potentiated by dietary sodium deficiency (8,9,13,14).
Thus, cortical tissue obtained from rats maintained on a sodium deficient
diet was used in this investigation.
Since further characterization of the receptor type mediating the
renin responses to dopamine administration is necessary, the present
study was designed to 1) provide additional in vitro evidence regarding
the involvement of a beta-adrenergic receptor mechanism in mediating the
effect of dopamine on renin secretion, by utilizing the phosphodiesterase
inhibiting agent, theophylline; 2) examine the possibility of dopaminespecific receptor participation, by evaluating the effect of the dopamine-receptor blocker, d-butaclamol; 3) determine if the renin secretory
responses to these agents are coupled with tissue cyclic AMP content
changes at various incubation times; and 4) evaluate if new synthesis
of renin occurs as a result of administration of these agents to our
cortical slice preparation.

CHAPTER II
LITERATURE REVIEW
A.

Control of Renin Secretion
There is no question as to the importance of the glycoprotein

hormone, renin (15), acting as a circulatory proteolytic enzyme, in
the control of arterial blood pressure (16) and in the primary regulation of aldosterone secretion and thus of sodium and blood volume homeostasis (17-19).

The mechanisms participating in the control of renin

release have been the subject of intensive study for numerous years.
Three major theories have been proposed to explain how a number of stimuli known to affect renin secretion activate the juxtaglomerular cells
that produce it in the kidney; 1) a "Baroreceptor" or "Stretch Receptor"
theory states that renin is regulated by changes in tone of the afferent
arteriolar walls in response to changes in renal perfusion pressure (20),
2) a "Macula Densa" Theory holds that the rate of renin secretion is inversely related to sodium and/or chloride concentration in the distal
tubular fluid, as sensed by specialized cells in that area (21), and 3)
a "Neural" Theory postulates that there is a sympathetic nervous regulation of renin secretion either directly through nerve terminals synapsing with the juxtaglomerular cells or indirectly via circulating
adrenal medullary catecholamines (20).

Additional factors such as cir-

culating angiotensin II, antidiuretic hormone (ADH), and intrarenal
prostaglandins also appear to play a role in the regulation of renin
3

4

secretion (21) although not as importantly as the three major ones, and
by mechanisms which are still largely unknown.

It is clear, however,

that in the live animal renin release depends to a large degree upon
the simultaneous interaction of all of these various stimuli.
1.

Baroreceptor Control of Renin Release
The development of the baroreceptor concept came about as a re-

sult of studies on renal hypertension.

Goldblatt found in the early

1930's that hypertension of renal origin could be induced by renal artery constriction and he, therefore, concluded that renal ischemia was
an important factor stimulating the release of renin from the kidney
(22).

Subsequent studies have demonstrated that reduced renal perfu-

sion pressure rather than an impaired renal blood flow is the primary
stimulator of renin release (23-25), although they both are interrelated to a certain degree.

This view led investigators to study the ef-

fect of changes in perfusion pressure on juxtaglomerular cell granulation as an index of juxtaglomerular cell synthetic activity and metabolism.

Tobian (26) found an inverse correlation between renal perfusion

pressure and juxtaglomerular cell granularity, which resulted in his
support of the existence of an intrarenal stretch receptor in the renal
afferent arteriole which responds to changes in blood pressure.

Added

evidence for the baroreceptor theory has been obtained through studies
utilizing the denervated, non-filtering dog kidney model, which effectively isolates the afferent arteriolar mechanism of renin release regulation for those mediated by the renal nerves and macula densa.

Uti-

lizing this model, Blaine and co-workers (27-29) found that the increase
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in renin release seen after hemorrhage occurred as a result of afferent
arteriole constriction and decreased renal perfusion pressure despite
the absence of macula densa and neural influences, supporting the concept of a renal vascular receptor involved in the regulation of renin
secretion.

Furthermore, the renin secretory responses to hemorrhage

were abolished when this vascular receptor was blocked by administration
of the smooth muscle relaxant, papaverine, to the denervated, non-filtering dog kidney (30).

Some investigators, however, have shown an increas-

ed renin release rate associated with dilatation of the afferent arteriole during renal autoregulation (31,32).
2.

Macula Densa Receptor Regulation of Renin Secretion
Electron microscopic studies have clearly shown that the macula

densa cells in the renal distal tubule are in close anatomical association with the juxtaglomerular cells (33,34).

The macula densa has

therefore been implicated as an additional regulatory site participating
in the overall control of renin secretion.

Whether the stimulus to the

macula densa to influence renin release is an increased (35) or decreased
(24,36,37,38) sodium load to that area, remains unclear.

Based on data

from numerous distal tubule microinjection studies, Thurau and co-workers
have suggested that it is an increase in sodium concentration rather than
load, in this area which is the signal influencing renin secretion (3941).

Meyer et al. (42) and Cooke (43) using osmotic diuretics to in-

crease sodium concentration to the macula densa have confirmed Thurau's
conclusions.

Conversely, Nash (35) has shown that an increase in sodium

flux across the macula densa cells into the interstitium surrounding the

6

juxtaglomerular cells is responsible for the resulting increase in renin

'
release •. Increased chloride load to the macula densa has also been
proposed as the possible signal for renin release (41,44).

In contrast,

Vander's experiments involving the use of diuretics during aortic constriction in order to vary distal tubular sodium load without altering
arterial pressure (38) have led to the view that a decreased sodium
load to the macula densa results in an increased release of renin.

Van-

der (45) and DiBona (46) have conducted experiments in which decreases
in both distal sodium load and concentration were produced by occluding
the ureter during mannitol diuresis.

Their results further support the

concept of decreased sodium load to the macula densa as the stimulus
for renin secretion.
3.

Humoral Control of Renin Release
Angiotensin II and antidiuretic hormone (ADH) are two circulating

factors known to exert an inhibitory effect on the secretion of renin
(47,48).

Shade (48), in experiments using dogs with a nonfiltering kid-

ney found that renal artery infusion of angiotensin II or antidiuretic
hormone inhibits renin secretion.

He suggested that these agents exert

their effects directly on the juxtaglomerular cells.

A direct negative

feedback action exerted by angiotensin II on renin release has been confirmed by others in vitro (3) and in vivo (49-51), although the mechanism involved remains unclear.
Bunag (47) and Vander (52) have confirmed Shade's findings concerning the inhibitory effect of ADH on renin release.

Moreover, Ta-

gawa (53) reports that increases in plasma ADH lowers plasma renin ac-

7

tivity in sodium deficient dogs.

Even though the exact mechanism involved

in the renin responses to ADH is not known, a direct effect is generally
accepted.

Vandongen's work in vitro supports this view (54).

Recently, intrarenal prostaglandins have been implicated in Che
control of renin secretion (61,62).

In vitro studies have shown that

PGE2 increases release of renin whereas PGFll has no effect on renin release in rabbit renal cortical cell suspensions (55).

Gerber (56) has

also demonstrated in vivo that administration of PGE 2 increases plasma
renin activity.

Conversely, Weber et al. (57,58) have shown that PGE2

has no effect on the secretion of renin in vitro and that PGF2a actually
decreased release in vitro and depressed plasma renin activity in

~·

Administration of prostaglandin precursors such as arachidonic acid and
of prostaglandin synthetase inhibitors such as indomethacin are known to
increase and decrease plasma renin activity, respectively, in the rabbit
(59).

Using filtering and nonfiltering kidneys in anesthetized dogs,

Seymour and Zehr (60) have shown that various intrarenal prostaglandins
have a direct effect on the juxtaglomerular cells to increase renin release.

In view of these conflicting data, further investigation is in

order to evaluate a possible regulatory action of prostaglandins on the
release of renin.
4.

Neural Control of Renin Release; Action of Sympathetic Nerves and

Catecholamines
The kidney cortex is innervated by the lesser splanchnic nerve,
a branch of the sympathetic nervous system (63), and a great supply of
sympathetic nerve terminals in close association with the juxtaglomeru-
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lar cells has been demonstrated (64-67).
ades

ago~

Thus, approximately two dec-

a direct neurogenic control of renin secretion was postulated

and a large body of evidence supporting this concept has been provided

since then (68-72).

A significant decrease in renin release occurs when

the kidney is denervated (69,70).

Electrical stimulation of the renal

nerves in the nonfiltering kidney results in an increase in the release
of renin when the baroreceptors are inactivated (71).

In some experi-

ments, renal vasoconstriction has been observed in association with an
increased renin activity after renal nerve stimulation (72).
Besides the peripheral neural control of renin release, central
nervous system stimulation has also been shown to modify renin responses
via the renal nerves (73-75).

In these studies, electrical stimulation

of the midbrain (73), pons (75), or medulla (74) increased renin release.
In all cases, the responses were abolished by renal denervation.

How-

ever, Ueda (73) observed a simultaneous increase in circulating catecholamines associated with diminution of the renin responses to midbrain
stimulation after renal denervation.

He thus suggested that the central

nervous system regulates release of renin through a circulating catecholamine mechanism.

Furthermore, the catecholamines epinephrine and nore-

pinephrine (71,76) and tyramine (77), an amine capable of releasing norepinephrine from nerve endings (78), are known to stimulate renin release
when infused directly into the renal artery.

In a recent study by John-

son (79), epinephrine and isoproterenol infused into the inferior vena
cava caused a marked increase in plasma renin activity, whereas renal
artery infusion of epinephrine did not increase plasma renin activity.
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L-propranolol blocked the increase in plasma renin activity caused by
vena cava infusion of epinephrine, suggesting an extrarenal beta-receptor mediation.
On the other hand, norepinephrine administration induces release
of renin when infused intravenously during aortic constriction (72) although Wathen et al. (76) disputes this.

Intravenous infusion of nor-

epinephrine and isoproterenol increases renin secretion

acco~ding

to

Ueda (80), a response that is inhibited by administration of propranolol
and not affected by denervation.

Thus, sympathetic catecholamines may

act either directly on the juxtaglomerular cells to stimulate renin release or indirectly by affecting the intrarenal receptors.
The direct effect of catecholamines on renin secretion has been
studied extensively utilizing various agonistic and antagonistic agents
in vitro to determine the mechanism mediating the renin release responses
to these agents (3-10, 14, 81-86).

Renal cortical slices (5-10,14), ren-

al cortical suspensions (81), isolated glomeruli (84), or isolated perfused kidney preparations (85,86) have been used in these studies to
evaluate a number of factors which may directly influence renin release,
and Braverman (87), Hammersen (88), and Corsini (89) have shown that renin release in vitro is a metabolically active process.
It is generally agreed from these in vitro studies that a betaadrenergic receptor mechanism is involved in the mediation of the stimulatory effect of norepinephrine on renin secretion (3-6,8,81-83) and
that this mechanism appears to utilize cyclic AMP as the intracellular
messenger (4-6,8-10,14-81).

Support for cyclic AMP participation has
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been obtained in in vivo (91-94) and in vitro (3,4,95,96) studies utilizing the phosphodiesterase inhibitor theophylline which effectively prevents the intracellularly generated nucleotide from being degraded, thus
potentiating the renin secretory responses to catecholamine stimulation.
The type of beta-adrenergic receptor that is involved in the direct regulation of renin release is still under debate.

Some studies

have shown that renin release responses are mediated via a beta1 or cardiac type receptor (97-99) while others (83,100) have demonstrated that
a betaz-type (peripheral vascular type) is inv9lved.
In addition to the stimulatory effect On renin release exerted
by norepinephrine via a beta-adrenergic receptor mechanism, Lopez et al.
(9) have shown that stimulation of renal alpha-adrenergic receptors by
large concentrations of norepinephrine inhibits renin

secret2~n

this effect is coupled with decreases in tissue cyclic AMP.

and that

This concept

of alpha-adrenergic receptor inhibition of renin release was clearly demonstrated by the fact that addition of alpha-adrenergic receptor antagonist agents result in removal of the renin release inhibition caused by
norepinephrine.

This view has been supported by others working with the

isolated rat kidney (101), the cortical slice system (4,7,8), or the live
animal (102).
5.

Dopaminergic Regulation of Renin Release
Dopamine is a catecholamine (3,4-dihydoxybenzene) (103) which is

structurally similar to its beta-hydroxylated derivative, norepinephrine.
Studies of the actions of dopamine indicate that many metabolic effects
produced by this catecholamine are different from those caused by nor-

ll
epinephrine (104-112), suggesting the existence of dopamine-specific receptors.

For instance dopamine turnover rates are greater in certain

areas of the brain than others even though norepinephrine concentration
is the same (113).

Also, despite the fact that over 50% of the total

catecholamine content of the mammalian brain is dopamine, Carlsson (114115), Sano (116), and others (117-118) have demonstrated that brain dopamine, unlike norepinephrine, is concentrated in a few specific areas,
namely the corpus striatum of the basal ganglia and substantia nigra of
the mesencephalon.

Additionally, dopaminergic neurons are identifiable

in the hypothalamus (119-120) , possibly terminating at the origin of the
hypophyseal portal system (119).

These neurons are thought to play a

role in the regulation of prolactin (121-122) and gonadotropin (123) release from the anterior pituitary gland.
In addition to its role as a neurotransmitter in the midbrain
and hypothalamus, numerous studies have shown that dopamine can exert
peripheral effects on organs controlled by the autonomic nervous system
(124) and on the coronary (104-106) and renal (108-112) vasculature.
Specifically, dopamine is known to 1) increase cardiac muscle force of
contraction and heart rate by an action on beta-adrenergic receptors
(104-106), 2) exert an effect on alpha-adrenergic receptors to cause
vasoconstriction in peripheral vascular beds (104,107) and 3) produce
vasodilatation in the kidney (108-110) via specific dopaminergic vasculature receptors (110-112).

McDonald and Goldberg (125) have shown

that intravenous infusion of dopamine stimulates renal blood flow, and
increases glomerular filtration rate and sodium diuresis.

Most of these
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renal effects by dopamine are inhibited by haloperidol, a specific dopamine-receptor blocking agent (112,126).

These findings are supportive

of the existence of a specific vascular receptor by which dopamine causes
renal vasodilatation and have recently been confirmed by Nakajima (127).
Dopamine has been identified in the kidney of several species
(128-129), and the release of dopamine from sympathetic nerves (130) and
the adrenal medulla (131) has been demonstrated.

Because of these obser-

vations, and in view of the evidence Goldberg has produced in support of
the existence of a specific dopamine receptor in the renal vasculature,
a number of laboratories are currently evaluating the potential role
which dopamine may play in the regulation of renin release from the renal
juxtaglomerular cells.
Various in vivo studies have demonstrated that dopamine either
increases (132-134) or decreases (135-136) renin secretion in the dog
or in man.

Such conflicting evidence is not unusual in view of the num-

ber of factors in the live animal which simultaneously interact to influence renin release.

Thus, in vitro studies have been undertaken in

which the direct effects of dopamine may be more effectively studied,
in the absence of hemodynamic, humoral, and other in vivo influences

(1,2,9,10).
Utilizing a rat renal cortical slice preparation, Henry et al.
(1) found that addition of dopamine at concentrations of 10-5M or greater
significantly increased renin release, and that the known beta-adrenergic
receptor blocker, propranolol, prevented the stimulatory effect of dopamine on renin secretion.

They concluded that dopamine directly stim-
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ulated renin release by a mechanism involving a beta-adrenergic receptor,
a view supported by recent observations of Quesada (2).

Additionally,

Lopez et al. (9,10) have shown that this direct stimulatory effect of
dopamine on renin release is coupled with tissue cyclic AMP changes,
which suggest the involvement of adenyl cyclase in the stimulatory pathway.
Data from studies by Nakajima et al. (127,137) utilizing spiroperidol, a dopamine receptor antagonist, in a rat kidney particulate
preparation indicate that specific dopamine receptors mediate the elevation of cyclic AMP levels in renal tissue after addition of dopamine
leading to renal vasodilation.

These observations by Nakajima and those

seen in our laboratory (9,10) constitute evidence for the existence of
a cyclic-AMP-mediated receptor mechanism by which dopamine influences
renal mechanisms.

However, these data do not elucidate whether or not

dopamine may influence renin secretion through an interaction with a
specific dopamine receptor, as opposed to its clear beta-adrenergic receptor mediation on renin release.

Furthermore, recent evidence by

Kebabian suggests that more than one type of dopamine receptor exists
(138).

In view of these conflicting results, further characterization

of the receptor type mediating the renin responses to dopamine is in
order.

c:IAPTER II I
MATERIALS AND METHODS

Thirty-six male Sprague-Dawley rats (Sprague-Dawley Co., Madison,
Wisconsin) with initial weights of 210 + 10 g were used in this study.
They were kept in a temperature-and-light-controlled room (23

± 2°C;
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hour light-12 hour dark photoperiod), two animals per cage, with unlimited access to distilled, deionized water.

The animals were fed a sodi-

um-deficient diet (Teklad Test Diet Co., Madison, Wisconsin), providing
less than 0.02 mEq of sodium per day for a period of 10-20 days.

They

were subsequently sacrificed by decapitation and their kidneys excised
and placed in Robinson's buffer at 4°C (139).

The isolated kidneys

were then gassed again for'30 sec with the same gas mixture.
Slices of renal cortex, approximately 0.3 mm thick, were prepared
from the decapsulated kidneys using a Stadie-Riggs microtome (A. Thomas
Co.).
ti~s

Each slice was subsequently divided into six similarly-sized secwhich were randomly distributed to incubation beakers containing

2.5 ml of Robinson's buffer media at 4°C.

The procedure was repeated

using slices from other cortical areas until each beaker contained 50 +
30 mg of homogeneously distributed cortical tissue.

The sliced tissue

was preincubated at 37°C for 15 min in a Shaking Dubnoff Metabolic Incubator (Precision Scientific Co.) under an atmosphere of 95% 02 - 5%

co 2 •

The preincubated tissue was then transferred to beakers containing

2.5 ml of fresh Robinson's buffer at 37°C and incubated for 5,20 or 60
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15
minutes under identical conditions as in the preincubation period.
One of each group of six tissue-containing beakers was used as
an untreated:. control sample, while the remaining tissue samples were
treated with dopamine (1o-3M; Sigma):. added either alone or in conjunction with the dopamine-receptor blocking agent d-butaclamol (1o-6M; Ayerst), its inactive isomeric form 1-butaclamol (10-6M), or the phosphodiesterase inhibitor theophylline (1o-3M).

D- and 1-butaclamol and theo-

phylline were also administered alone to the tissue preparation.

In a

simultaneous study:. the specific dopamine receptor agonist, apomorphine

(10-~), was added to the tissue preparation either alone or with dopamine (10-3M).

The dopamine beta-hydroxylase inhibitor FLA-63 (10-4M;

Regis) was added to all samples to prevent conversion of dopamine to
norepinephrine in the tissue system (11,12).
Theophylline:. the blocking agents, apomorphine, and FLA-63 were
added to the tissue preparation prior to both the pre-incubation and
incubation periods, while dopamine was added prior to the incubation
period only.

D- and 1-butaclamol, dopamine, apomorphine, and FLA-63

were preparaed in a 0.1% ascorbic acid solution (Sigma) to prevent oxidation (5), while theophylline was prepared in Robinson's buffer.
Following incubation:. the supernatant medium was collected and
stored at -20°C until assayed for renin concentration by angiotensin I
radio~unoassay

(142).

The incubated tissue was immediately frozen

on dry-ice, homogenized in 1 ml of 8% trichloracetic acid:. transferred
to tubes containing 5 drops of 0.1 N HCl, vortexed for 5 sec, and stored
at -20°C until assayed for cyclic AMP content by a modification of the
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protein-binding assay of Gilman (141).

In some instances, the incubated

tissue was collected for determination of its renin content.

The tissue

was purified by a series of dialysis steps and measured for renin concentration by radioimmunoassay of angiotensin I.
A.

Determination of Renin Concentration
Renin concentration in incubated supernatant was estimated in-

directly by measuring the amount of angiotensin I generated when aliquots
of the renin-containing samples were allowed to react with dog renin substrate in the presence of an appropriate inhibitor of converting enzyme
and angiotensinases.

When these enzymes are inactivated, the accumula-

tion of angiotensin I during a given generation period reflects renin
activity.

Blockade of converting enzyme and angiotensinase activity was

achieved in this study by the use of a 1% solution of phenylmethylsulfonylfluoride (PMSF; 142).
To generate angiotensin I, the frozen samples were thawed in an
ice bath at 4°C and vortexed for ten seconds.

Aliquots of 0.025 m1

frGm each sample were then transferred to tubes containing 0.1 m1 of
saturated NaCl.

Six-hour nephrectomized dog plasma containing renin

substrate (angiotensinogen) and previously treated with PMSF (0.05 ml/ml
plasma) was then added to each tube (0.4 ml/tube).

The mixture was in-

cubated for one hour at 37°C and diluted with one m1 of distilled, deionized water.

The samples were vortexed for five sec, covered with

aluminum foil, and placed in a boiling water bath for three min to prevent further angiotensin I generation.
to cool to 25°C and stored at -20°C.

The samples were then allowed
The amount of angiotensin I gener-
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ated was measured by a modification of Angiotensin I ( 125I) Radioimmunoassay

(N~w

England Nuclear) •

Renin concentration was expressed in ng/mg/

hr -(ng of angiotensin I generated/ mg of tissue/ hour of generation) •
B.

Tissue Renin Determination
Tissue collected for determination of renin content was homogen-

ized in 1 m1 of 0.9% NaCl at 4°C and centrifuged for 15 min at 3500 g.
The supernatant was subsequently dialyzed for 24 hours against an EDTAacetic acid buffer (pH 3.3), followed by heating to 32oc for 1 hour to
selectively denature endogenous renin substrate and angiotensinases,
and dialyzed again for 24 hours against an EDTA-phosphate buffer (pH
7.5) as described by Skinner (143).
The purified tissue homogenates were then used to generate angiotensin I as described previously and subsequently measured for renin concentration by Angiotensin I ( 125 I) Radioimmunoassay (New England Nuclear) •

The values were expressed in ng of angiotensin I generated/ mg wet

tissue/ hour of generation.
C.

Determination of Tissue Cyclic Adenosine 3',5'-Monophosphate (cAMP)

Content
The frozen tissue homogenates collected for cAMP determination
were thawed in an ice bath at 4°C, and centrifuged at 4000 g for ten
min at 4°C.

The supernatant was transferred, while the protein pellet

was discarded.

Two m1 of water-saturated ether were added to each

sample, vortexed for ten sec, and the ether phase aspirated and discarded.

This extraction procedure was repeated three additional times.
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The cAMP-containing water soluble phase was then decanted into vials
previously placed on dry
lyophyilized.

ice~

and the frozen samples were subsequently

The lyophilized material was then stored at -2ooc until

assayed for cAMP content by a modification of the competitive protein
binding assay of Gilman (141) • Tissue cAMP concentration was expressed
in pmol/mg (pmol of cAMP/mg wet tissue).
Calculations
Statistical significance of the data was evaluated by Student's
paired and unpaired t tests using a programmable desk top calculator
(Hewlett-Packard) at Argonne National Laboratory

(Argonne~

Illinois).

A Linear Regression Analysis was performed on the control data (144) •

CHAPTER IV

RESULTS
Resting renin release and tissue cyclic AMP content of untreated
(control) renal cortical tissue from sodium deficient rats are shown in
Fig. 1.
0.62; p

Renin release increased linearly with time of incubation (r:
<

0.001).

In contrast to renin, tissue cyclic AMP content val-

ues were maximal at 20 min of incubation and decreased by 60 min to levels seen at 5-m.in incubation.
The effect of 1o-3M dopamine on three parameters, renin release,
tissue renin content, and tissue cyclic AMP at various incubation times,
is depicted in Fig. 2.

Renin release responses to dopamine administra-

tion gradually increased over control by 5 and 20 min and were significantly greater by 60 min.

In contrast, cyclic AMP content values in re-

sponse to added dopamine appeared significantly greater than those of
control samples as early as 5 min of incubation.

Although mean tissue

renin content of the dopamine-treated samples appeared higher than that
of controls by about 60 nanograms at 60 min, this difference was not
statistically significant.
The effect of the phosphodiesterase inhibitor theophylline

(10-3M) added alone or together with dopamine (1o-3M) on the same three
parameters in relation to time of incubation, is demonstrated in Fig. 3.
Theophylline appeared to increase the renin release responses to added
dopamine at 20 and 60 min, while significantly potentiating the cyclic
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AMP responses to dopamine administration at the same time periods.

Theo-

phylline py itself significantly increased renin release by 60 min, not
only in relation to controls but in regard to dopamine alone (p < 0.02).
Cyclic AMP content changes in response to theophylline alone were significantly potentiated when compared to those exerted by dopamine alone at all
times of incubation (p < 0.01, p < 0.02, p < 0.02 for 5,20, and 60 min,
respectively), but were not different from those seen in response to
theophylline plus dopamine treatment at corresponding.times.
Mean tissue renin content at 60 min appeared increased by about
25 nanograms in response to theophylline plus dopamine and by an additional 85 nanograms in the presence of theophylline alone when compared
to that observed in response to dopamine added alone, although these differences were not significant.
Addition of the specific dopamine-receptor blocker d-butaclamol
(1o-6M) to the cortical slice preparation increased the mean renin release levels in relation to those seen with dopamine alone at 60 min,
but not significantly (Fig. 4).

Also, d-butaclamol administration did

not further alter the significant stimulation of tissue cyclic AMP levels seen with dopamine alone at the same time period.

By itself, d-buta-

clamol had no effect on renin release or tissue cyclic AMP content.

Mean

tissue renin content in the presence of d-butaclamol added together with
dopamine was increased by about 40 nanograms in relation to that seen in
response to dopamine alone, but the difference was not significant.
L-butaclamol at 1o-6M, added alone or with dopamine was ineffective in altering the renin release and cyclic AMP levels seen with
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dopamine alone (Fig. 5).

A 60 nanogram increase in tissue renin content

occurred .in response to dopamine plus 1-butaclamol treatment relative to
control at 60 min, but this difference was again not significant.
Figure 6 summarizes the results of this study utilizing theophylline and d-butaclamol, and those obtained in a parallel study with apomorphine, a dopamine-receptor agonist.

From this figure it is clear that in

addition to the data reported in this section, apomorphine (1o-6M) prevented the stimulatory effect of 1o-3M dopamine on renin release and cyclic
AMP content at 60 min incubation.
servations will be discussed.

The overall significance of these ob-
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Figure 1.

Renin release rate and tissue cyclic AMP content of unstim-

ulated (control) renal cortical slices from sodium deficient rats
at incubation times of 5, 20, and 60 min.

The renin release data

represent the mean control value + S.E. of 14-32 observations for
each time period.

Similarly, the cyclic AMP content data represent

the mean control value + S.E. of 12-14 observations for each time
period.

The dopamine beta-hydroxylase inhibitor FLA-63 (10-4M) was

added to all samples in this and subsequent experiments.
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Figure 2.

Effect of 1o-3M dopamine on renin release, tissue cyclic

AMP content, and tissue renin content of renal cortical slices from
sodium deficient rats.

The data represent the mean renin release

rate+ S.E. of 14-32 observations, and the mean tissue cyclic AMP
content+ S.E. of 12-14 nontreated (control) and dopamine-treated
samples at various incubation times.

The data also show that mean

tissue renin content+ S.E. of 23 observations in control and dopamine-treated samples at 60 min incubation.
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Figure 3.

Changes in renin release, tissue cyclic AMP content, and

tissue renin content, in response to 1o-3M dopamine and 1o-3M theophylline, added together or separately to renal cortical slices
from sodium deficient rats.

The data represent the mean renin re-

lease change + S.E. of 7-13 observations, the mean tissue cyclic
AMP content change± S.E. of 9-11 observations for each treatment
at 3 incubation times.

The mean renin release rates for nontreated

(control) tissue at 5, 20, and 60 min incubation were 2.55 + .276
ng/mg wet tissue/hr, 3.86 + .801 ng/mg/hr, and 10.28 + 1.01 respectively.

The corresponding mean control cyclic AMP content values

were, respectively, .397 + .032 pmol/mg, .616 + .076 pmol/mg, and
.437 + .046 pmol/mg.

The mean control tissue renin content at 60

min was 1419 + 103 ng/mg/hr.
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Figure 4.

Changes in renin release, cyclic AMP content, and tissue

renin content in response to 10-3M dopamine and 10-6 d-butaclamol,
added together or separately to renal cortical slices from sodium
deficient rats.

The data represent the mean renin release change

+ S.E. of 2-18 observations, the mean tissue cyclic AMP content
change + S.E. of 2-12 observations, and the mean tissue renin content change+ S.E. of 13 observations for each treatment at various
incubation times.

The mean control (nontreated) values for renin

release rate, tissue cyclic AMP content, and tissue renin content,
for each time period are the same as those in Figure 3.
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Figure 5.

Changes in renin

release~

tissue cyclic AMP content, and

tissue renin content in response to 1o-3M dopamine and 1o-6M 1butaclamol, added alone or together to renal cortical slices from
sodium deficient rats.

The data represent the mean renin release

change+ S.E. of 4-14 observations, the mean tissue cyclic AMP content change+ S.E. of 2-11 observations, and the mean tissue renin
content change + S.E. of 10 observations for each treatment at various incubation times.

The mean control (untreated) values for ren-

in release rate, tissue cyclic AMP content, and tissue renin content,
for each time-period are the same as those described in Figure 3.
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Figure 6.

Changes in renin release, tissue cyclic AMP content, and

tissue renin content in response to dopamine (1o-3M) added alone
or together with 1o-3M theophylline, 1o-6M d-butaclamol, or 1o-6M
apomorphine, to renal cortical slices from sodium deficient rats.
The data represent the mean renin release change± S.E. of 2-18
observations, the mean tissue cyclic AMP content change± S.E. of
2-12 observations, and the mean tissue renin content change+ S.E.
of 9-24 observations for each treatment at various incubation times.
The mean control (untreated) renin release rate, tissue cyclic AMP
content, and tissue renin content at various times of incubation,
are the same as those indicated in Figure 3.

The corresponding

'

mean control values at 3 incubation times, for treatments involving
dopamine alone or together with apomorphine were, respectively,
2.56 + 0.48, 4.69 + 1.51, and 10.60 + 1.39 ng/mg/hr for renin release; 0.39 + 0.03, 0.53 + 0.09, and 0.45 + 0.01 pmol/mg for cyclic
AMP content; and 489 + 399 ng/mg/hr for tissue renin content at 60
min.
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CHAPTER V

DISCUSSION
Renal cortical slice preparations have been successfully utilized
in numerous studies to evaluate the direct effect of catecholamines and
other agents on renin release (5-10, 14), or to examine renin secretory
rates in unstimulated cortical tissue (6, 90, 145, 146).

The results

obtained in this study support previous observations in studies utilizing
rat kidney slice systems (6, 90, 145, 146), that renin release in resting
renal tissue is directly proportional to time of incubation which is to
be expected of metabolically active, oxygen-consuming (147) endocrine
tissue.

Furthermore, these data provide added evidence for the postu-

lation that resting renin secretory rates in renal -slices from sodium
deficient rats are comparably greater than those seen in sliced tissue
obtained from rats maintained on sodium replete diets (6, 90, 145),
which may reflect an increased responsiveness of the juxtaglomerular
cells in the sodium deficient state.
Studies in this laboratory (9,10) have recently shown that dopamine at 1o-3M can directly stimulate renin release through a beta-adrenergic receptor mechanism apparently mediated by tissue cyclic AMP
changes, which confirm previous observations by Henry ( 1) and Quesada
(2).

The data generated in the present study offer further support for

the concept of a cyclic AMP-mediated beta-receptor regulation of renin
release by dopamine, by demonstrating that cyclic AMP content of the
34
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incubated tissue in response to dopamine administration was significantly
increased over that of controls as early as 5 min of incubation, whereas
renin release appeared significantly stimulated only after 60 min of incubation.

These observations are consistent with the model proposed by

Sutherland (148) regarding mediation of stimulus-hormonal responses by
adenylate cyclase/cyclic AMP, and they agree with the postulated betaadrenergic receptor mechanism of action by which other catecholamines
stimulate renin secretion (3,5,7-10).

Furthermore, the results of this

study utilizing the phosphodiesterase inhibitor theophylline, provide
added evidence for this concept by showing that both tissue cyclic AMP
and renin secretory rates were potentiated in the presence of this agent,
as suggested in previous studies with other catecholamines (4,81).

Al-

though the data are not conclusive in this regard, the apparent increase
in tissue renin content in response to dopamine and theophylline administration in this study, may be suggestive of new synthesis of renin in
addition to increased release as suggested by Katz in studies with dog
renal cortical slices (149).

Effective binding of dopamine to receptors

other than dopamine-specific ones is not unusual, since Goldberg (150)
has demonstrated that this amine has the biochemical flexibility to bind to
beta- and perhaps also to alpha-adrenergic receptors.

Thus, it appears

that dopamine stimulates renin release by a beta-adrenergic receptor
mechanism, a view supported by other investigators (1,2,10) who have
shown that the stimulatory effect exerted by dopamine on renin release
can be suppressed by addition of the beta-receptor blocker, propranolol.
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Recently, Quesada et al. (2) have produced evidence showing that
the dopamine-receptor blocking agent, haloperidol, potentiates the renin
release responses to dopamine administration.

The results of the present

study utilizing the dopamine-receptor blocker, d-butaclamol, agree with
their observations and further suggest that dopamine-specific receptors
may have no effect or may participate in an inhibitory fashion in the
regulation of renin release.

Whether or not tissue cyclic AMP is also

involved in mediating this apparent inhibitory control of renin secretion by dopamine is not clear, since d-butaclamol administration did
not further alter the content of the nucleotide in relation to that
seen with dopamine alone.

However, data from another study using the

dopamine-receptor agonist agent, apomorphine, appear to indicate that
decreases in tissue cyclic AMP content may mediate the action of the
inhibitory component of dopamine, in view of the fact that specific
stimulation o·f dopamine receptors by this agent prevented the increase
in renin release and tissue cyclic AMP content observed with dopamine
alone.

Thus, dopamine may stimulate renin release via a beta-receptor

mechanism involving cyclic AMP content changes and it may inhibit it by
its interaction with a dopamine-specific receptor.
Although the possibility of a dual regulatory control exerted
by dopamine on renin secretion is attractive and a similar concept has
been postulated in regard to the regulation of renin release by norepinephrine (6,8,101,102), further work is needed to determine if the apparent
inhibition mediated by a dopamine receptor is real, since the results seen
in this study with the inactive isomer, 1-butaclamol (151) are contradic-
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tory and do not fit the proposed model.

Therefore, additional doses of

apomorphine and d,- and 1-butaclamol need to be evaluated and other known
dopamine-receptor agonist and antagonist agents must be examined, before
this question can be effectively answered.
In summary, the data reported in this study suggest that, 1)
dopamine is capable of directly stimulating the renal juxtaglomerular
cells to influence renin release via a

beta-adrenerg~c

receptor mechan-

ism involving tissue cyclic AMP changes; 2) new synthesis of renin, in
addition to stimulation of its release, may result from the interaction
of dopamine with this postulated beta-adrenergic receptor; and 3) dopamine may also exert a simultaneous inhibitory regulation of renin release via a dopaminergic-receptor mechanism, but further investigation
is needed before this possibility can be properly evaluated.
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